复发难治性多发性骨髓瘤治疗的现状与挑战

Current Status and Challenges in Treatment of Relapsed/Refractory Multiple Myeloma

多发性骨髓瘤是一种无法治愈的恶性血液病,近年来众多药物的应用改善了患者的生存和生活质量,然而疾病最终会进展为复发难治性多发性骨髓瘤,新药的基础研究和临床应用变得至关重要。本文评估了复发难治性多发性骨髓瘤治疗试验中的数据,列举了目前的治疗进展。此外,多发性骨髓瘤与基因组异常、免疫正常化、蛋白质稳态密切相关,以这三个方面为靶点进行研究将进一步指导精准治疗的发展。

Multiple myeloma remains an incurable hematological malignancy. In recent years, the application of many agents has improved the survival and life quality of patients. However, the disease will eventually progress into relapsed/refractory multiple myeloma. Hence, the basic research and clinical application of novel agents have become essential. This article evaluates data from treatment studies for relapsed/refractory multiple myeloma and lists current treatment advances. Furthermore, multiple myeloma is closely related to genomic abnormalities, immune normalization, and protein homeostasis. Targeting these aspects will further guide the development of precise treatment.